- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:55 | Realty Income, Stryker und mehr Dividenden im global market - Ex-Tag 30.09.2026 | 7 | Wiener Börse | ||
| 10:38 | Stryker: Diese Cyberfolgen sind noch nicht ausgestanden | 6 | Maximilian Berger | ||
| Mi | Can Stryker Vehicle Demand Support General Dynamics' Growth? | 10 | Zacks | ||
| Di | TD Cowen cuts Stryker stock price target to $298 on margin concerns | 13 | Investing.com | ||
| 18.09. | Canaccord cuts Stryker stock price target on manufacturing woes | 28 | Investing.com | ||
| 11.09. | Stryker still working through cyberattack after-effects, stock down more than 10% this week | 50 | MassDevice | ||
| STRYKER CORPORATION CDR Aktie jetzt für 0€ handeln | |||||
| 09.09. | Stryker To Acquire ZuriMED To Expand Shoulder And Rotator Cuff Portfolio | 19 | pulse2.com | ||
| 09.09. | BMO senkt Kursziel für Stryker nach revidierten Schätzungen auf 317 $ | 95 | Investing.com Deutsch | ||
| 09.09. | BMO cuts Stryker stock price target on revised estimates to $317 | 23 | Investing.com | ||
| 09.09. | Wells Fargo cuts Stryker stock price target on revenue concerns | 35 | Investing.com | ||
| 08.09. | Lieferkettenprobleme belasten Stryker: Aktie bricht um 7,7 % ein | 207 | Investing.com Deutsch | ||
| 08.09. | Stryker drops after comments on vascular and ortho segments | 135 | Seeking Alpha | ||
| 04.09. | Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio? | 30 | Insider Monkey | ||
| 03.09. | Stryker Launches FDA-Cleared Apple Vision Pro Surgical App | 27 | Zacks | ||
| 01.09. | Stryker führt erste Operation mit FDA-zugelassener App für Apple Vision Pro durch | 42 | Investing.com Deutsch | ||
| 01.09. | Stryker completes first surgery using Apple Vision Pro app | 6 | Investing.com | ||
| 01.09. | Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center | 528 | PR Newswire | SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information
Stryker announced the successful completion of the first... ► Artikel lesen | |
| 01.09. | Is Stryker Stock Underperforming the Nasdaq? | 22 | Barchart.com | ||
| 31.08. | Stryker to acquire ZuriMed to boost shoulder offerings | 5 | MassDevice | ||
| 31.08. | Stryker to acquire ZuriMED and its rotator cuff repair system | 9 | Investing.com |
1 2 3 4 5 Weiter >>
133 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 16,030 | 0,00 % | Aktien New York: Dow mit schwachem Wochenauftakt - Nasdaq im Plus | NEW YORK (dpa-AFX) - An der Wall Street hat der Handel am Dienstag nach dem verlängerten Wochenende schwach begonnen. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst vor bald... ► Artikel lesen | |
| DISC MEDICINE | 65,24 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,320 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 280,81 | 0,00 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| TANGO THERAPEUTICS | 24,910 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 39,340 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,920 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 35,930 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 14,470 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME | 4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet need First patients have been enrolled in 4SIGHT global Phase 3 trial... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,615 | 0,00 % | Citizens reiterates Summit Therapeutics stock rating on trial data | ||
| CULLINAN THERAPEUTICS | 14,810 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio | Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE)... ► Artikel lesen | |
| IMMUNOME | 21,415 | 0,00 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| CLIMB BIO | 11,660 | 0,00 % | Climb Bio, Inc.: Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy | ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse... ► Artikel lesen | |
| PARABILIS MEDICINES | 31,200 | 0,00 % | Parabilis Medicines, Inc.: Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates | Advanced zolucatetide across multiple Wnt/ß-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with... ► Artikel lesen | |
| RELAY THERAPEUTICS | 17,470 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen |
STRYKER CORPORATION CDR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 11,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STRYKER CORPORATION CDR finden Sie auf Wallstreet Online.